Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-0301
Abstract: Abstract Purpose: We hypothesized that inhibition and trapping of PARP1 alone would be sufficient to achieve antitumor activity. In particular, we aimed to achieve selectivity over PARP2, which has been shown to play a role… read more here.
Keywords: parpi; inhibitor; generation; parp1 ... See more keywords
Abstract 2730: Preclinical characterization of the anti-PD-L1 monoclonal antibody LY3300054
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-2730
Abstract: Modulating the PD-L1/PD-1 axis in man through function blocking antibodies can release potent anti-tumor immunity, leading to durable objective responses across multiple tumor types. Here we describe the discovery and preclinical characterization of LY3300054, a… read more here.
Keywords: preclinical characterization; antibody; monoclonal antibody; anti monoclonal ... See more keywords
Abstract 4561: Preclinical characterization of GLS-010 (AB122): A fully humanized clinical-stage anti-PD-1 antibody
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4561
Abstract: INTRODUCTION: Exhausted T cells express high levels of several immune checkpoint proteins, including the programmed death-1 (PD-1) receptor. Preclinical and clinical data support the role of the PD-1/PD-L1 axis in promoting tumor evasion by curtailing… read more here.
Keywords: preclinical characterization; antibody; gls 010; characterization gls ... See more keywords
Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-22-0057
Abstract: Novel therapeutic approaches combining immune checkpoint inhibitors are needed to improve clinical outcomes for patients with cancer. Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint molecule that inhibits T-cell activity and antitumor immune responses, acting… read more here.
Keywords: lag; relatlimab; characterization relatlimab; relatlimab human ... See more keywords
Synthesis and preclinical characterization of novel ruthenium (II) arene complexes for the treatment of solid tumors.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e14512
Abstract: e14512Background: The development of metallopharmaceutics has placed organometallic ruthenium (II) complexes in the spotlight of interest. Although platinum agents are still the main therapeutic op... read more here.
Keywords: ruthenium; characterization novel; synthesis preclinical; preclinical characterization ... See more keywords
Advances in the preclinical characterization of the antimicrobial peptide AS-48
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Microbiology"
DOI: 10.3389/fmicb.2023.1110360
Abstract: Antimicrobial resistance is a natural and inevitable phenomenon that constitutes a severe threat to global public health and economy. Innovative products, active against new targets and with no cross- or co-resistance with existing antibiotic classes,… read more here.
Keywords: antimicrobial peptide; range; action; advances preclinical ... See more keywords
Preclinical Characterization of a Novel Anti-Cancer PD-L1 Inhibitor RPH-120
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2021.723038
Abstract: RPH-120 is a novel fully human anti-PD-L1 IgG1 monoclonal antibody with specifically designed Asn300Ala mutation in Fc fragment. Surface plasmon resonance assay showed that affinity of the RPH-120 to the dimeric form of human PD-L1-Fc… read more here.
Keywords: novel; rph 120; preclinical characterization; anti ... See more keywords